HysensBio
PrivateLast Round
Private Equity
Feb 1, 2026
Est. Valuation
$75.9M
Total Funding Raised
$21.57M
Company Overview
HysensBio operates in Healthcare & Life Sciences and is based in South Korea. Its latest recorded funding round was a VC Round in July 2023.
HysensBio is a drug discovery company that develops dental treatment technology using a cell activation platform to provide therapies for dentin hypersensitivity and dental caries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HysensBio Comparables
Compare HysensBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mintech-Bio | 78% | |
| Stemden | 77% | |
| Toregem BioPharma | 74% |
For institutional investors. Book with your work email.
HysensBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Feb 1, 2026 | ||||
| VC Round | Jul 24, 2023 | ||||
| Series C | May 7, 2021 | ||||
| Series B | May 29, 2019 | ||||
| Series A | Mar 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HysensBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DAYLI Partners | Series B |
| Korea Investment Partners | Private Equity, Series B, Series A, Series C |
| KB Investment | Private Equity, VC Round |
| DS Asset Management | Series C, VC Round |
| Timefolio Asset Management | Series B, Series C |
| KTB Ventures | Series C |
| Daol Investment | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2025
Won Pitch Competition at ADA Forsyth dentech 2025.
- Jan 1, 2025
Attended the Pitch Competition at ADA Forsyth dentech 2025.
For institutional investors. Book with your work email.
HysensBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HysensBio's valuation, stock price, and market status.
Is HysensBio a public or private company?
HysensBio is a private company.
What is the current stock price of HysensBio?
HysensBio is a private company, so its shares have no public market price. Caplight tracks HysensBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HysensBio worth (valuation)?
HysensBio's valuation is estimated at $75.9M based on funding round data.
Can I buy HysensBio stock?
HysensBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HysensBio's last funding round?
HysensBio's most recent funding round was Private Equity on February 1, 2026.
Who are the main investors in HysensBio?
Key investors in HysensBio include Korea Investment Partners, Korea Investment Partners.
Will HysensBio IPO soon?
No public IPO plans have been announced for HysensBio.
How can I track HysensBio secondary market activity?
Caplight tracks bids, offers, and trades in HysensBio's shares on secondary markets.